ADC Therapeutics (ADCT) Other Non-Current Assets (2019 - 2026)

ADC Therapeutics (ADCT) has reported Other Non-Current Assets for 8 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.

• Quarterly Other Non-Current Assets rose 7.14% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (up 7.14% YoY) and the FY2025 annual result came in at $1.2 million, up 4.82% from the prior year.
• Other Non-Current Assets grew to $1.2 million in Q1 2026 per ADCT's latest filing, from $1.2 million in the prior quarter.
• Over the last five years, Other Non-Current Assets for ADCT reached as high as $1.4 million in Q2 2023 and fell as low as $711000.0 in Q4 2023.
• A 5-year average of $1.1 million and a median of $1.2 million in 2024 frame the typical range for Other Non-Current Assets.
• Annual changes were most pronounced in 2022 — Other Non-Current Assets soared 160.71% — and 2024, when it sank 31.25%.
• Year by year, Other Non-Current Assets stood at $902000.0 in 2022, then retreated by 21.18% to $711000.0 in 2023, then soared by 63.29% to $1.2 million in 2024, then climbed by 4.82% to $1.2 million in 2025, then grew by 2.38% to $1.2 million in 2026.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $1.2 million, $1.2 million, and $1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.